deltatrials
Completed PHASE2 NCT00006244

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma

Sponsor: Fred Hutchinson Cancer Center

Conditions Refractory Multiple Myeloma Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma
Interventions aldesleukin in vitro-treated peripheral blood stem cell transplantation melphalan recombinant interferon alfa
Updated 10 times since 2017 Last updated: Jun 16, 2017 Started: Feb 29, 2000 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016

A PHASE2 clinical study on Refractory Multiple Myeloma and Stage I Multiple Myeloma, this trial is completed. The trial is conducted by Fred Hutchinson Cancer Center and has accumulated 10 data snapshots since 2000. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. May 2022 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Completed PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  3. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Feb 2017 — Jul 2017 [monthly]

    Completed PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Seattle, United States